Alogliptin

證據等級: L5

預測適應症: 0 個

ALOGLIPTIN: Drug Repurposing Evaluation Report

One-Sentence Summary

Alogliptin (DB06203) is a DPP-4 inhibitor primarily used for the treatment of type 2 diabetes mellitus. Currently, the TxGNN model has no predicted new indications for this drug, and there are no clinical trials or publications associated with a repurposing direction. This candidate requires further data collection before evaluation can proceed.

Quick Overview

Item	Content
Original Indication	Type 2 diabetes mellitus (DPP-4 inhibitor; no Taiwan-approved indication on record)
Predicted New Indication	None — TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	L5 (No predictions or supporting studies available)
Taiwan Market Status	✗ Not marketed (未上市)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, the TxGNN model has not generated any predicted new indications for alogliptin. Without a repurposing hypothesis, a mechanistic rationale cannot be evaluated at this time.

Based on publicly available knowledge, alogliptin is a selective dipeptidyl peptidase-4 (DPP-4) inhibitor that works by preventing the degradation of incretin hormones (GLP-1 and GIP), thereby increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. It is approved in multiple markets (including the US, EU, and Japan) for the management of type 2 diabetes mellitus, often in combination with metformin or pioglitazone.

Note: The Evidence Pack lists the mechanism of action as unavailable. The above description is based on established pharmacological literature for alogliptin. Once DrugBank API data is retrieved (see Data Gap DG002), this section should be updated with the authoritative MOA description.

Clinical Trial Evidence

Currently no related clinical trials registered for any repurposing indication.

(This section will be populated once TxGNN generates predicted indications and evidence is collected.)

Literature Evidence

Currently no related literature available for any repurposing indication.

(This section will be populated once TxGNN generates predicted indications and evidence is collected.)

Taiwan Market Information

Alogliptin currently holds no marketing authorizations in Taiwan (TFDA). No licenses were found in the regulatory query performed on 2026-03-29.

Safety Considerations

Please refer to the package insert for safety information.

Note: TFDA package insert data and DrugBank safety warnings were not available at the time of this report. Key warnings, contraindications, and drug-drug interactions remain to be collected (see Data Gaps below).

Data Gaps Requiring Resolution

The following critical data gaps were identified during evidence pack assembly:

Gap ID	Category	Item	Severity	Impact	Remediation
DG001	Drug Level	TFDA Package Insert Warnings / Contraindications	Blocking	Cannot enter S1 safety preliminary assessment	Download and parse package insert PDF from TFDA website
DG002	Drug Level	Mechanism of Action (MOA)	High	Affects mechanistic relevance analysis	Query DrugBank API

Conclusion and Next Steps

Decision: Hold

Rationale: There are no TxGNN-predicted new indications for alogliptin at this time. Additionally, two critical data gaps (TFDA package insert and MOA) remain unresolved — one of which (DG001) is classified as Blocking and prevents safety assessment from proceeding.

To proceed, the following is needed:

Run or re-run TxGNN prediction for alogliptin to determine if any new indications are generated
Resolve DG001 (Blocking): Obtain TFDA package insert warnings and contraindications, or source equivalent safety data from another regulatory authority (e.g., FDA, EMA, PMDA) given alogliptin is not marketed in Taiwan
Resolve DG002 (High): Retrieve detailed mechanism of action from DrugBank API
Reassess market availability: Since alogliptin is not marketed in Taiwan, consider whether the drug can be sourced through special import channels or clinical trial supply if a repurposing indication is identified
Re-evaluate once the above data is collected and TxGNN predictions are available
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.